Latest Manufacturing Milestones News

Patrys Limited is pushing forward with a proprietary injectable formulation of quetiapine targeting the lucrative delirium treatment market, leveraging a faster, lower-cost FDA 505(b)(2) regulatory pathway and strong patent protection.

dorsaVi has moved from design to silicon manufacturing with the tape-out of its first 22-nm RRAM-CMOS validation chip, aiming to prove its advanced memory platform for AI and robotics applications.

Patrys has assigned its deoxymab intellectual property to Yale University in a deal granting it half of all future commercialisation revenue, reducing capital needs while keeping long-term upside.

AdAlta has met a key US$1 million milestone payment under its China collaboration, gaining critical clinical data and securing proprietary materials for Australian manufacturing of its lead CAR-T therapy BZDS1901.

Aurora Labs has begun batch deliveries of its AU4 micro gas turbine propulsion systems to Sovereign Propulsion Systems, marking a key step towards real-world flight testing and commercialisation in defence and UAV markets.

Critical Resources has scaled its solid-state battery program from coin cells to full-format pouch cells, marking a key manufacturing milestone with electrochemical testing now underway. The next phase aims to integrate its proprietary sulphur-free solid-state electrolyte into these cells.

Island Pharmaceuticals is accelerating development of its broad-spectrum antiviral Galidesivir, progressing clinical, regulatory, and manufacturing milestones under the FDA Animal Rule pathway with expanded USAMRIID collaboration and biodefence positioning.

Island Pharmaceuticals has kicked off GMP manufacturing of its antiviral Galidesivir to support late-stage Marburg virus studies under the FDA Animal Rule, marking a key step towards regulatory submission and biodefence readiness.

AdAlta has engaged specialist advisors to streamline US FDA regulatory processes for its CAR-T therapy BZDS1901, which has shown rare complete tumour clearance in advanced mesothelioma patients.

AdAlta has secured A$2.5 million in a strategic placement to push its lead CAR-T therapy BZDS1901 through critical US FDA regulatory steps and establish Australian manufacturing, building on promising clinical responses in advanced mesothelioma.

Percheron Therapeutics has secured $2.2 million through an entitlement offer to fund the next stage of its HMBD-002 oncology program, with manufacturing underway and key data presentations lined up at major cancer conferences.

Amplia Therapeutics reported mature ACCENT trial data showing improved survival and multiple complete responses with narmafotinib, alongside a GMP production milestone and CFO appointment.